bioRxiv Science⌕ Search

Biology subjects

Seeger-Nukpezah, T.

Publications and source records attributed to Seeger-Nukpezah, T..

3 recordsLinked to original sources

Tumour-derived factors prime microglia for immune checkpoint-mediated T-cell regulation

Tumour-associated microglia are major regulators of the immune microenvironment in brain malignancies, yet the early mechanisms by which tumour-derived signals shape their immune phenotype remain poorly understood. We used quantitative proteomic analysis on microglia upon tumour exposure and observed extensive remodelling of the microglial proteome following exposure to tumour-conditioned media, indicating that soluble mediators represent the dominant drivers of early microglial activation. Microglia reprogramming was characterized by coordinated upregulation of inflammatory mediators together with proteins involved in antigen presentation and T-cell regulation, including MHC-I, PD-L1 and Galectin-9. Flow cytometric validation using multiple murine and human cell models confirmed the increased expression of PD-L1 and MHC-I on microglia following exposure to tumour-derived conditioned media. Subsequently, tumour-conditioned microglia promoted expression of the inhibitory receptors PD-1 and TIM-3 on T-cells after coculture. Importantly, integration of publicly available single-cell RNA sequencing datasets and cell-cell communication analysis further demonstrated that this immune-regulatory program is recapitulated in microglia from patients with brain tumours. Together, our findings identify an early, soluble factor-driven microglial activation program that precedes direct tumour contact and integrates inflammatory activation with immune checkpoint regulation. These results provide a mechanistic framework for the early establishment of an immunosuppressive brain tumour microenvironment and highlight microglial immune checkpoint pathways as potential targets for therapeutic intervention.

cancer biology↗

Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2

Targeted inhibition of Brutons Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenstroms Macroglobulinemia, Mantle cell lymphoma and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal antibodies have been initiated at rapid pace, with the biological understanding between their synergistic interactions lagging behind. Here, we have evaluated the synergy between BTK inhibitors and monoclonal antibody therapy via macrophage mediated antibody dependent cellular phagocytosis (ADCP). Initially, we observed increased ADCP with ibrutinib, whilst second generation BTK inhibitors failed to synergistically interact with monoclonal antibody treatment. Kinase activity profiling under BTK inhibition identified significant loss of Janus Kinase 2 (JAK2) only under ibrutinib treatment. We validated this potential off-target effect via JAK inhibition in vitro as well as with CRISPR/Cas9 JAK2-/- experiments in vivo, showing increased ADCP and prolonged survival, respectively. This data supports inhibition of the JAK-STAT signaling pathway in B-cell malignancies in combination with monoclonal antibody therapy to increase macrophage mediated immune responses.

cancer biology↗

Individual nephron proteomes connect morphology and function in proteinuric kidney disease

In diseases of many parenchymatous organs, heterogenous detoriation of individual functional units determines the clinical prognosis. However, the molecular characterization of these subunits remains a technological challenge that needs to be addressed in order to better understand pathological mechanisms. Sclerotic and proteinuric glomerular kidney disease is a frequent and heterogeneous disease which affects a fraction of nephrons, glomeruli and draining tubules, to variable extents, and for which no treatment exists. Here, we developed and applied an antibody-independent methodology to investigate heterogeneity of individual nephron segment proteomes from mice with proteinuric kidney disease. This \"one-segment-one-proteome-approach\" defines mechanistic connections between upstream (glomerular) and downstream (tubular) nephron segment populations. In single glomeruli from two different mouse models of sclerotic glomerular disease, we identified a coherent protein expression module consisting of extracellular matrix protein deposition (reflecting glomerular sclerosis), glomerular albumin (reflecting proteinuria) and LAMP1, a lysosomal protein. This module was associated with a loss of podocyte marker proteins. In an attempt to target this protein co-expression module, genetic ablation of LAMP1-correlated lysosomal proteases in mice could ameliorate glomerular damage. Furthermore, individual glomeruli from patients with genetic sclerotic and non-sclerotic proteinuric diseases demonstrated increased abundance of lysosomal proteins, in combination with a decreased abundance of the mutated gene products. Therefore, increased glomerular lysosomal load is a conserved key mechanism in proteinuric kidney diseases, and the technology applied here can be implemented to address heterogeneous pathophysiology in a variety of diseases at a sub-biopsy scale

physiology↗